ArticleAnnals of medicine and surgery (2012)2018
A cohort study of prognostic factors associated with recurrence or metastasis of gastrointestinal stromal tumor (GIST) of stomach.
Article in Annals of medicine and surgery (2012), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current treatment and outcomes of pediatric gastrointestinal stromal tumors (GIST): a systematic review of published studies.Pediatric surgery international · 2021Pooled it
- Preoperative Prediction of High Mitotic Count in Gastrointestinal Stromal Tumors Using CT Features and Serologic Indicators: An Interpretable Model with Multicenter External Validation.Journal of inflammation research · 2026Article
- Immunotherapy in gastrointestinal stromal tumors: Current landscape and future horizons.World journal of clinical oncology · 2025Article
- Survival disparities and predictors in gastric cancer: a population-based study from Kazakhstan (2012-2023).Frontiers in oncology · 2025Article
- Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.Current treatment options in oncology · 2024Review
- Understanding Gastric GIST: From Pathophysiology to Personalized Treatment.Journal of clinical medicine · 2024Review
- Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers.Molecular cancer · 2023Review
- Gastric and Small Intestine Gist: Results of 156 Cases in 20 Years.Journal of gastrointestinal cancer · 2022Article
- The Relationship of Clinicopathological Findings and PDGFR-β Expression With Tumor Recurrence in Gastrointestinal Stromal Tumors.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021Article
- Is There Pathological Uniformity between the Periphery and Center of a Gastrointestinal Stromal Tumor?Journal of clinical medicine · 2021Article
- Assessment of Systemic Inflammation and Nutritional Indicators in Predicting Recurrence-Free Survival After Surgical Resection of Gastrointestinal Stromal Tumors.Frontiers in oncology · 2021Article
- Decreasing the burden: An unusual GIST presentation, a case report.International journal of surgery case reports · 2020Article
- Establishment and Verification of Synchronous Metastatic Nomogram for Gastrointestinal Stromal Tumors (GISTs): A Population-Based Analysis.Gastroenterology research and practice · 2020Article
- Performance of risk stratification systems for gastrointestinal stromal tumors: A multicenter study.World journal of gastroenterology · 2019Article
- A rare case of incidental finding of GIST during sleeve gastrectomy: Case report.International journal of surgery case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. The major risk factors of recurrence and metastasis are mitotic index and tumor size. This study investigates the risk of recurrence and metastasis in solely gastric GIST. The primary outcome is to evaluate risk of recurrence and metastasis. The secondary outcome is to analyse survival rates of patients who have recurrence and metastasis after curative resection.
methodA cohort of patients who underwent curative resection of gastric GIST between January 2006 to December 2016 was reviewed. The diagnosis was confirmed with positive CD34, DOG1 or KIT (CD117) immunohistochemistry. Risk factors of recurrence and metastasis were analyzed.
resultsSixty-eight patients who received curative resection and diagnosed as gastric GIST were included in this study. Twenty (29.41%) had recurrence or metastasis. The median follow up time was 31.95 months. The mostcommon type of surgery was partial gastric resection. There were statistically-significant differences between mitotic index 6 HPF or 6 HPF in tumor size 0-5 cm, 5-10 cm and 10 cm and the risk of recurrence or metastasis (p-value 0.036). In tumors sized 6-10 cm, patients with mitotic index 6 HPF had longer survival than patients with mitotic index 6 HPF (p-value 0.0147).
conclusionThe factor that determines the outcome of recurrence or metastasis in solely gastric GIST is high mitotic index count. Patients who have abdominal pain may be suspected as advanced disease. The type of operation and tumor size are not associated with recurrence or metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.